Am­i­cus briefs fly in as IRA 'fair price' dead­line looms

Last year
Pharma
Law

Mer­ck adds third cer­vi­cal can­cer nod for Keytru­da, bring­ing to­tal ap­provals to 39

Last year
R&D
Pharma

FDA ap­proves Ver­tex and CRISPR's Cas­gevy as first CRISPR-edit­ed ther­a­py for be­ta-tha­lassemia

Last year
Cell/Gene Tx
FDA+

No­vo Nordisk restarts ad­ver­tis­ing for obe­si­ty drug We­govy with new cam­paign

Last year
Pharma
Marketing

Mar­ket­ingRx roundup: Phar­ma and biotech lead in salary sat­is­fac­tion; Pfiz­er cel­e­brates 175 years

Last year
Pharma
Marketing

Doud­na’s new ven­ture; Aclaris CEO to step down; Tome’s $114M liv­er dis­or­der deal with Genevant

Last year
News Briefing

How phar­ma gi­ants like GSK and Bris­tol My­ers are us­ing tech to shape their fu­ture

Last year
Health Tech

Look­ing past COPD, Re­gen­eron CSO George Yan­copou­los says Dupix­en­t's 'next big thing' is re­vers­ing al­ler­gies

Last year
R&D

Deer­field adds an­oth­er aca­d­e­m­ic part­ner in $130M Wash­ing­ton Uni­ver­si­ty pact

Last year
Startups
Deals

Al­lakos halves work­force, drops lead in­flam­ma­to­ry pro­gram

Last year
People
R&D

Up­dat­ed: Vivek Ra­maswamy gives up pres­i­den­tial bid, en­dors­es Trump, no plans to re­turn to Roivant

Last year
People

Ger­man trade union op­pos­es Bay­er’s busi­ness split pro­pos­al

Last year
Pharma

Dis­co de­buts with €20M seed round to ad­vance sur­faceome-based plat­form, with sup­port from Ab­b­Vie

Last year
Financing
Startups

Mid-stage CNS biotech Al­to Neu­ro­science files for NYSE list­ing

Last year
Financing
Startups

Four buy­outs (and one ru­mor that didn’t ma­te­ri­al­ize); Iso­mor­phic Lab­s' first phar­ma deals; A CAR-T IPO; #JPM24 ...

Last year
Weekly

Ex­clu­sive: Au­toim­mune CAR-T biotech Kyver­na Ther­a­peu­tics is con­sid­er­ing an IPO next month

Last year
Financing
Startups

Bio­Mar­in's chief com­mer­cial of­fi­cer step­ping down, search for suc­ces­sor be­gins

Last year
People
Pharma

PhRMA, Eli Lil­ly, oth­er drug com­pa­nies push back on FDA's draft guid­ance about com­mu­ni­cat­ing off-la­bel use

Last year
Pharma
FDA+

Econ­o­mists, health pol­i­cy ex­perts say J&J's IRA ar­gu­ments are 'over­ly sim­plis­tic'

Last year
Pharma
Law

Eval­u­ate buys fore­cast­ing group to build out pre­dic­tion soft­ware and ser­vices

Last year
Deals
Marketing

The Bell Labs of biotech: Stu­art Schreiber has bil­lion­aire sup­port for new bio­med­ical in­sti­tute 

Last year
People
Startups

In­sur­ance gi­ant Unit­ed­Health shares tum­ble with high­er med­ical ex­pens­es de­spite strong earn­ings

Last year
Health Tech

No­var­tis qui­et­ly used a PRV to speed the ap­proval of its new rare blood dis­or­der drug

Last year
Pharma

Ji Xing buys Bio­gen’s acute is­chemic stroke drug; Ex­elix­is/BioIn­vent part­ner­ship ends; Clin­Choice's deal in SEA

Last year
News Briefing
First page Previous page 217218219220221222223 Next page Last page
A service from the Financial Times